Evogene Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.19 loss in 3Q 2021)

Evogene (TLV:EVGN) Third Quarter 2022 Results

Key Financial Results

• Net loss: US$6.54m (loss narrowed by 14% from 3Q 2021).
• US$0.16 loss per share (improved from US$0.19 loss in 3Q 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Evogene Earnings Insights

Looking ahead, revenue is forecast to grow 108% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Asia.

Performance of the market in Israel.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with Evogene (including 1 which is significant).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.